DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $47,284,022 | +10.1% | 2,292,003 | +57.5% | 0.27% | +9.6% |
Q2 2023 | $42,946,552 | +71.2% | 1,455,322 | +33.7% | 0.25% | +83.1% |
Q1 2023 | $25,084,524 | -17.2% | 1,088,738 | 0.0% | 0.14% | -25.3% |
Q4 2022 | $30,277,804 | +67.6% | 1,088,738 | +84.9% | 0.18% | +54.2% |
Q3 2022 | $18,068,000 | +4.3% | 588,738 | 0.0% | 0.12% | +20.4% |
Q2 2022 | $17,327,000 | +506.9% | 588,738 | +563.5% | 0.10% | +512.5% |
Q1 2022 | $2,855,000 | -27.9% | 88,738 | 0.0% | 0.02% | -15.8% |
Q4 2021 | $3,958,000 | -11.6% | 88,738 | 0.0% | 0.02% | -5.0% |
Q3 2021 | $4,477,000 | -35.7% | 88,738 | 0.0% | 0.02% | -35.5% |
Q2 2021 | $6,961,000 | +37.4% | 88,738 | 0.0% | 0.03% | +40.9% |
Q1 2021 | $5,067,000 | -31.8% | 88,738 | 0.0% | 0.02% | -21.4% |
Q4 2020 | $7,433,000 | +108.7% | 88,738 | -10.7% | 0.03% | +100.0% |
Q3 2020 | $3,562,000 | +40.5% | 99,400 | -5.2% | 0.01% | +27.3% |
Q2 2020 | $2,536,000 | +38.1% | 104,900 | 0.0% | 0.01% | 0.0% |
Q1 2020 | $1,837,000 | – | 104,900 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
Artal Group S.A. | 802,899 | $16,564 | 0.71% |